Abstract 3715
Background
The main objective of this project is to develop a mobile application (APP) for monitoring and controlling the management of the therapeutic regime in this group of people, with a view to strengthening communication among patients and health professionals, favoring adherence to therapeutic indications and responding, in a timely manner and in a proactive manner, to the symptoms or complications that may arise associated with the disease, thereby improving the efficacy of the therapy, preventing complications and improving its perception of health and quality of life. In fact, health interventions must transform behavior towards the desired improvement and empowerment of the person, thus facilitating self-management. Its final presentation will be on the form of an APP, which will improve the well-being and quality of life of people with cancer, bringing gains in efficiency and health outcomes, broadening the sense of the adequacy of policies of health. The expected results with the implementation of this APP are: improve and monitor patient adherence to oral and supportive therapies; to prevent, the appearance of complications or symptoms associated with the treatment, through preventive indications of self-care (green alert level); improve patients responses, through self-care uncontrolled complications (yellow alert level); signaling to the patient and health services, uncontrolled symptoms with high severity (red alert level); improve the efficiency of health teams with regard to self-management of the disease and produce and disseminate knowledge in oncology. At this time the project is already at an advanced stage of development. Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique.
Trial design
Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique. The project has already been tested on an initial sample of 40 patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract